InflaRx NV Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
14.7%projected annual EPS growth
Analyst Coverage
8analysts covering
FY EPS (est.)
-$0.35next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Marketable Securities Quarterly39.7MTarget: Sufficient to fund operations into 2027
Quarterly Net Loss Quarterly-5.6MTarget: Narrowing losses through restructuring
Gohibic (vilobelimab) Revenue Quarterly0.0Target: Reactive sales under EUA only
Watch Items
- Izicopan (INF904) Phase 2b readiness in Hidradenitis Suppurativa (HS)Trigger: FDA feedback on study design and endpointsAction: Initiate Phase 2b trial and secure development partner
- Izicopan PK bridging study in ChinaTrigger: First patient dosed / study completion in 2026Action: Leverage data to expand proof-of-concept studies in additional geographies
- BARDA-sponsored 'Just Breathe' Phase 2 study for vilobelimab in ARDSTrigger: Interim data readouts or enrollment milestonesAction: Maintain operational support while minimizing commercial spend
Research as of 19 Jun 2026